Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock.
acute myocardial infarction
cardiogenic shock
inotrope
mechanical circulatory support
renal replacement therapy
revascularization
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
pubmed:
30
10
2021
medline:
1
3
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
Background The randomized DOREMI (Dobutamine Compared to Milrinone) clinical trial evaluated the efficacy and safety of milrinone and dobutamine in patients with cardiogenic shock. Whether the results remain consistent when stratified by acute myocardial infarction remains unknown. In this substudy, we sought to evaluate differences in clinical management and outcomes of acute myocardial infarction complicated by cardiogenic shock (AMICS) versus non-AMICS. Methods and Results Patients in cardiogenic shock (n=192) were randomized 1:1 to dobutamine or milrinone. The primary composite end point in this subgroup analysis was all-cause in-hospital mortality, cardiac arrest, non-fatal myocardial infarction, cerebrovascular accident, the need for mechanical circulatory support, or initiation of renal replacement therapy (RRT) at 30-days. Outcomes were evaluated in patients with (n=65) and without (n=127) AMICS. The primary composite end point was significantly higher in AMICS versus non-AMICS (hazard ratio [HR], 2.21; 95% CI, 1.47-3.30;
Identifiants
pubmed: 34713704
doi: 10.1161/JAHA.121.021570
pmc: PMC8751815
doi:
Substances chimiques
Dobutamine
3S12J47372
Milrinone
JU9YAX04C7
Banques de données
ClinicalTrials.gov
['NCT03207165']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e021570Subventions
Organisme : CIHR
Pays : Canada
Références
J Am Coll Cardiol. 2018 Jul 10;72(2):173-182
pubmed: 29976291
Circ Cardiovasc Interv. 2010 Oct;3(5):491-8
pubmed: 20923986
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
N Engl J Med. 2018 Nov 1;379(18):1699-1710
pubmed: 30145971
N Engl J Med. 2021 Aug 5;385(6):516-525
pubmed: 34347952
Cochrane Database Syst Rev. 2018 Jan 29;1:CD009669
pubmed: 29376560
Circulation. 2017 Oct 17;136(16):e232-e268
pubmed: 28923988
N Engl J Med. 2019 May 30;380(22):2146-2155
pubmed: 31141635
JACC Cardiovasc Interv. 2019 Oct 14;12(19):1877-1888
pubmed: 31521648
Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):40-47
pubmed: 29463462
Crit Care. 2016 Jul 04;20(1):208
pubmed: 27374027
N Engl J Med. 2017 Dec 21;377(25):2419-2432
pubmed: 29083953
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
JAMA Intern Med. 2020 Oct 1;180(10):1317-1327
pubmed: 32833024
N Engl J Med. 2012 Oct 4;367(14):1287-96
pubmed: 22920912
N Engl J Med. 1999 Aug 26;341(9):625-34
pubmed: 10460813
JAMA. 2006 Jun 7;295(21):2511-5
pubmed: 16757723
Eur Heart J. 2019 Aug 21;40(32):2671-2683
pubmed: 31274157
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618
pubmed: 30879324
JAMA. 2007 Apr 18;297(15):1657-66
pubmed: 17387132
Cardiovasc Revasc Med. 2016 Jul-Aug;17(5):333-8
pubmed: 27050627
Crit Care Med. 2008 Aug;36(8):2257-66
pubmed: 18664782